| Literature DB >> 32020726 |
Hideyoshi Kaga1, Yoshifumi Tamura1,2, Kageumi Takeno1,2, Saori Kakehi1,2, Yuki Someya2, Takashi Funayama1, Yasuhiko Furukawa1, Ruriko Suzuki1, Daisuke Sugimoto1, Satoshi Kadowaki1, Miho Nishitani-Yokoyama3, Kazunori Shimada2,3, Hiroyuki Daida2,3, Shigeki Aoki2,4, Adria Giacca5, Hiroaki Sato1, Ryuzo Kawamori1,2, Hirotaka Watada1,2,6,7.
Abstract
Individuals with a monophasic glucose response curve (GRC) during a 75-g oral glucose tolerance test have a higher risk for type 2 diabetes than those with a biphasic GRC. However, no studies have addressed the association between GRC type and insulin clearance. Thus, we studied 49 healthy non-obese Japanese men. We divided study participants into the monophasic or biphasic group based on the shape of their GRC. We evaluated tissue-specific insulin sensitivity and insulin clearance using a two-step hyperinsulinemic-euglycemic clamp. The monophasic group had more visceral fat, lower insulin clearance and lower muscle insulin sensitivity than the biphasic group, whereas liver and adipose tissue insulin sensitivity, and insulin secretion were comparable. In conclusion, healthy non-obese men with a monophasic GRC have lower insulin clearance and muscle insulin sensitivity.Entities:
Keywords: Insulin clearance; Insulin resistance; Shape of glucose response curve
Mesh:
Substances:
Year: 2020 PMID: 32020726 PMCID: PMC7378447 DOI: 10.1111/jdi.13227
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Clinical characteristics of the biphasic and monophasic groups
| Overall ( | Biphasic group ( | Monophasic group ( |
| |
|---|---|---|---|---|
| Age (years) | 40.2 ± 5.3 | 39.9 ± 5.5 | 40.3 ± 5.2 | 0.811 |
| BMI (kg/m2) | 23.1 ± 1.0 | 22.9 ± 1.2 | 23.2 ± 0.9 | 0.331 |
| Family history of type 2 diabetes (%) | 14 (28.6%) | 4 (22.2%) | 10 (32.3%) | 0.453 |
| Body fat (%) | 20.1 ± 5.0 | 18.8 ± 4.0 | 20.9 ± 5.4 | 0.159 |
| Fasting plasma glucose (mg/dL) | 93.2 ± 6.8 | 93.6 ± 6.5 | 93.0 ± 7.1 | 0.778 |
| Fasting serum insulin (μU/mL) | 4.9 ± 2.1 | 4.36 ± 1.83 | 5.20 ± 2.14 | 0.169 |
| AUC‐glucose during OGTT (mg·min/dL·103) | 15.6 ± 2.3 | 14.5 ± 1.7 | 16.2 ± 2.4 |
|
| AUC‐insulin during OGTT (μU·min/mL·103) | 5.2 ± 2.8 | 4.4 ± 2.4 | 5.7 ± 3.0 | 0.144 |
| Insulinogenic index | 0.95 ± 0.68 | 1.10 ± 0.68 | 0.86 ± 0.68 | 0.236 |
| Free fatty acid (μEq/L) | 335 ± 105 | 322.4 ± 110.5 | 342.6 ± 103.4 | 0.523 |
| HbA1c (%) | 4.9 ± 0.2 | 4.9 ± 0.2 | 4.9 ± 0.2 | 0.701 |
| High‐molecular‐weight adiponectin (ng/mL) | 1.82 ± 1.21 | 2.01 ± 1.34 | 1.71 ± 1.14 | 0.402 |
| Intramyocellular lipid in TA (S‐fat/Cre) | 3.2 ± 1.9 | 2.7 ± 1.8 | 3.5 ± 1.9 | 0.158 |
| Intramyocellular lipid in SOL (S‐fat/Cre) | 12.8 ± 6.8 | 11.7 ± 6.7 | 13.5 ± 6.9 | 0.370 |
| Intrahepatic lipid (%) | 1.9 ± 3.2 | 1.8 ± 3.3 | 2.0 ± 3.3 | 0.878 |
| Abdominal visceral fat area (cm2) | 75.3 ± 28.0 | 62.6 ± 24.2 | 82.7 ± 27.8 |
|
| Abdominal subcutaneous fat area (cm2) | 106 ± 40 | 94.2 ± 38.0 | 113.6 ± 39.9 | 0.102 |
| VO2peak (mL/kg per min) | 36.0 ± 7.0 | 37.3 ± 8.3 | 35.2 ± 6.1 | 0.320 |
| MCRI during the second step | 610.9 ± 83.3 | 641.7 ± 71.9 | 593.0 ± 85.4 |
|
| SSSI during the second step (μU/mL) | 36.4 ± 5.2 | 33.8 ± 4.2 | 37.9 ± 5.2 |
|
| %Reduction in EGP/SSSI during the first step (%/μU·mL−1) | 3.7 ± 1.0 | 3.9 ± 0.9 | 3.7 ± 0.9 | 0.424 |
| Rd during the second step (mg/kg FFM·min−1) | 8.6 ± 2.0 | 9.1 ± 2.3 | 8.3 ± 1.8 | 0.189 |
| Rd/SSSI during the second step (mg/kg FFM·min−1 ·μU−1·mL) | 0.24 ± 0.08 | 0.27 ± 0.09 | 0.22 ± 0.06 |
|
| %FFA suppression/insulin during the first step (%/μU·mL−1) | 4.54 ± 1.35 | 4.57 ± 1.26 | 4.52 ± 1.42 | 0.904 |
Data are the mean ± standard deviation.
AUC, area under the curve; BMI, body mass index; Cre, creatine signal; EGP, endogenous glucose production; FFM, fat‐free mass; HbA1c, glycated hemoglobin; MCRI, metabolic clearance rate of insulin; OGTT, oral glucose tolerance test; Rd, rate of disappearance; S‐fat, methylene signal intensity; SOL, soleus muscle; SSSI, steady‐state serum insulin; TA, tibialis anterior muscle.
Bold values indicate P values with significant differences between the two groups.
Figure 1(a) Plasma glucose and (b) insulin levels during oral glucose tolerance tests in individuals in the monophasic group (solid lines) and biphasic group (dashed lines). Data are reported as the mean ± standard deviation.